Immune-evasive human islet-like organoids ameliorate diabetes.
Eiji YoshiharaCarolyn O'ConnorEmanuel GasserZong WeiTae Gyu OhTiffany W TsengDan WangFritz CayabyabYang DaiRuth T YuChristopher LiddleAnnette R AtkinsMichael DownesRonald M EvansPublished in: Nature (2020)
Islets derived from stem cells hold promise as a therapy for insulin-dependent diabetes, but there remain challenges towards achieving this goal1-6. Here we generate human islet-like organoids (HILOs) from induced pluripotent stem cells and show that non-canonical WNT4 signalling drives the metabolic maturation necessary for robust ex vivo glucose-stimulated insulin secretion. These functionally mature HILOs contain endocrine-like cell types that, upon transplantation, rapidly re-establish glucose homeostasis in diabetic NOD/SCID mice. Overexpression of the immune checkpoint protein programmed death-ligand 1 (PD-L1) protected HILO xenografts such that they were able to restore glucose homeostasis in immune-competent diabetic mice for 50 days. Furthermore, ex vivo stimulation with interferon-γ induced endogenous PD-L1 expression and restricted T cell activation and graft rejection. The generation of glucose-responsive islet-like organoids that are able to avoid immune detection provides a promising alternative to cadaveric and device-dependent therapies in the treatment of diabetes.
Keyphrases
- induced pluripotent stem cells
- type diabetes
- glycemic control
- blood glucose
- stem cells
- cardiovascular disease
- cell therapy
- cell proliferation
- endothelial cells
- transcription factor
- weight loss
- blood pressure
- cancer therapy
- metabolic syndrome
- mesenchymal stem cells
- big data
- pluripotent stem cells
- artificial intelligence
- bone marrow
- machine learning
- deep learning
- drug induced
- small molecule
- loop mediated isothermal amplification
- combination therapy
- wound healing